All Oncology News

The FDA has expanded the approval for sorafenib to include the treatment of patients with RAI-resistant metastatic differentiated thyroid cancer, based a substantial prolongation in PFS over placebo in the DECISION trial.

Aldoxorubicin (formerly INNO-206) has demonstrated response rates that culminated in a higher incidence of stable disease when compared to doxorubicin as a first-line treatment for patients with advanced soft tissue sarcomas.

In this age of sequestration and health reform, 340B is getting a closer look by lawmakers-causing critics and advocates to line up to debate its merits.

Eribulin has demonstrated a high level of antitumor activity that was equivalent or superior to vincristine across several sarcoma xenograft models, including at low dose levels, suggesting the drug may effectively treat pediatric patients with sarcoma.

OncLive® is pleased to announce that the Wistar Institute has joined its Strategic Alliance Partnership program.

Eroding reimbursement rates and a shift from intravenous (IV) to oral chemotherapy are combining to threaten the viability of many community oncology practices.

A new test has been developed to identify the difference between malignant and benign nodules in the thyroid gland, which could potentially reduce the number of unnecessary surgeries, according to an announcement from The University of Pittsburgh Schools of the Health Sciences.

Over the past few years, seven new drugs have gained approval from the FDA for the treatment of patients with metastatic renal cell carcinoma. Primarily these approaches target angiogenesis and mTOR. The advent of these molecularly targeted therapies has significantly improved the standard of care for patients with RCC.

Two studies presented at this year's ASCO meeting suggest that a significant proportion of patients with cancer want to include the cost of therapy in their discussion of treatment options with their physician, regardless of insurance coverage.

Where Medicare patients receive their chemotherapy treatment makes a difference in the number of chemotherapy sessions that they receive on average.

The investigational anti-PD-1 immunotherapy MK-3475 has demonstrated an overall survival rate of 81% at one year in patients with advanced melanoma, according to additional data from a phase Ib clinical trial presented at the 10th International Congress of the Society for Melanoma Research in Philadelphia.

Delivering high-quality cancer care continues to be a daunting problem for the US healthcare system because of a combination of factors, including an aging population, a shrinking work force, the rising cost of therapies, and a complex disease state and treatment regimen.

Urologists who treat men with prostate cancer are 2.5 times more likely to refer patients to intensity-modulated radiation therapy centers, especially if they have a financial stake in the IMRT center.

The investigational autologous dendritic cell vaccine AGS-003 successfully activated a cytotoxic T cell response that correlates with a prolongation in survival for patients with metastatic renal cell carcinoma

The highest expense reported by community oncology practices continues to be attributable to drugs and biologics, according to "2013 Trends in Community Cancer Centers," a survey sponsored by the Association of Community Cancer Centers.

Acting ahead of schedule, the FDA has granted an accelerated approval to ibrutinib as a treatment for patients with mantle cell lymphoma who have received at least one prior therapy.

Everolimus provides clinical benefit to patients with papillary metastatic renal cell carcinoma, offering promising overall survival results and a tolerable side-effect profile, investigators found in a study presented during the 2013 European Cancer Congress in Amsterdam.

One oncology practice in Florida seems to have been able to adapt its practice model, taking advantage of economies of scale, and identifying new revenue streams, while still providing quality care and keeping its oncologists satisfied professionally.

A systematic review finds limited evidence of benefit.

Goal is to identify tests and treatments of little to no benefit.

The FDA has approved obinutuzumab plus chlorambucil as a first-line treatment for patients with chronic lymphocytic leukemia, based on clinical trial data demonstrating that the combination more than doubled median PFS over the chemotherapy agent alone.

Marketing and commercial distribution of ponatinib has been temporarily suspended, following an ongoing FDA investigation that revealed an increased frequency of arterial thrombosis and severe narrowing of the blood vessels.

Intervention doubled palliative care consultations; lowered in-hospital mortality and hospital readmission rates.

Hyperfractionated radiotherapy improved overall survival rates compared to standard and accelerated radiotherapy when administered without concomitant chemotherapy in patients with locally advanced head and neck squamous cell carcinoma.

Newest OncLive partner is a renowned translational cancer center that is at the forefront of comprehensive cancer treatment and research into advanced targeted therapies.

Recommendations issued by the NCI and ASCO.

The PD-1 blocking antibody nivolumab continues to demonstrate sustained clinical activity in previously treated patients with advanced non-small cell lung cancer.

The FDA has assigned a priority review designation to ramucirumab as a second-line treatment for patients with advanced gastric cancer.

IBM's computer will be used to identify effective cancer care.

The phase III PREVAIL trial of enzalutamide in chemotherapy-naïve patients with advanced prostate cancer has been stopped early after meeting its co-primary endpoints of overall survival and radiographic progression-free survival